Wales’ life science hub: six months on

29th January 2015

Wales’ life science hub: six months onIan Barwick

pharmaphorum speaks to Dr Ian Barwick, chief operating officer of the Life Sciences Hub Wales, about where the group stands six months from launch and how its partnership with a... Read more

Uncovering the hidden value in CLM

28th January 2015

Uncovering the hidden value in CLMJacky Law

Jacky Law reports on why so many companies are struggling to activate closed-loop marketing and how content management systems can help.The thinking behind closed-loop marketing (CLM) was always deceptively simple.... Read more

Does real world evidence matter in Health Technology Assessments?

27th January 2015

Does real world evidence matter in Health Technology Assessments?Daniel Liden, Ashley Jaksa, Yin Ho

Health Technology Assessment (HTA) agencies usually rely on randomised controlled trials for clinical data when evaluating drugs, but these do not always tell the entire story. Both biopharmaceutical companies and... Read more

The role an unmet need plays in driving innovation

26th January 2015

The role an unmet need plays in driving innovationCassandra Rix

As healthcare budgets tighten and patients' expectations increase, pharma must go beyond simply supplying the pills and work to provide services and technologies that address broader unmet needs.Historically, pharma innovation... Read more


£14m boost to stratified medicine research

29th January 2015

£14m boost to stratified medicine researchLinda Banks

Stratified medicine collaborations in the UK are set to benefit from a further £13.7 million cash injection from the Medical Research Council (MRC) to investigate cancer, heart disease, asthma and... Read more

AZ puts genome editing at heart of its drug discovery

29th January 2015

AZ puts genome editing at heart of its drug discoveryStaff reporter

AstraZeneca (AZ) has become the latest big pharma company to become excited by the prospect of gene editing techniques, signing four new deals to deploy the technology across its drug... Read more

Amgen riding high on 2014 results

29th January 2015

Amgen riding high on 2014 resultsLinda Banks

Amgen has announced a rise in Q4 revenues of 6 per cent, with full-year revenues increasing 7 per cent to $20.1 billion, based on strong performances from Enbrel and across... Read more

Momentum building behind tau as Alzheimer's target

28th January 2015

Momentum building behind tau as Alzheimer's targetStaff reporter

After years of playing second fiddle to amyloid as a drug target in Alzheimer's disease, there are signs of increasing interest in the development of tau protein-targeting drugs.Earlier this month,... Read more

Audio & Video

Live Tweetchat: Managing COPD in the rea…


Working in partnership, Atlantis Healthcare and pharmaphorum present a Tweetchat focussed on the real world challenges patients face in managing their COPD,... View more

Live webinar/debate - Feb 4th - COPD, co…

Join the COPD webinar/debate



COPD is a widespread, costly and largely preventable condition which affects over 300 million people worldwide and is recognised... View more

On demand webinar: The Price is Right? -…



With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what is next, what are the... View more

Now on demand - real world insight into …

The Diabetes Debate


Now available on demand (free to access) - originally broadcast on October 29th 2014.

Non-adherence to self-management regimens in diabetes is globally... View more

White Papers

Computer Gaming: The Future of Decision-…

Computer Gaming: The Future of Decision-Making for Life Sciences?

How can life science brands identify winning strategic decisions when there are so many variables to consider? One route is via 'road-testing' decisions ahead of sign-off under computer game simulated... View info

How do doctors want to engage with pharm…

How do doctors want to engage with pharma on new products?Dr Tim Ringrose

With more than 80 per cent of European doctors saying they want to stay abreast of new developments about pharmaceutical products, it is important to understand how they wish to... View info

Modelling patient behaviour to improve s…

Modelling patient behaviour to improve self-management in diabetesDr Sinéad NíMhurchadha & Jeremy Sayers

An understanding of health psychology is essential to helping patients adhere to their medication and lifestyle regimens. This report hones in on how the COM-B model of behaviour provides a... View info

"The future ain’t what it used to b…

"The future ain’t what it used to be"Paul Stuart-Kregor

Preparation is key to creating and maintaining a strong drugs pipeline. However, the statistics demonstrate that successful product commercialisation strategies are not always implemented. Products are developed for which there... View info

Further News & Articles

Novartis expects 10 NME filings by end-2016

Novartis told investors today that it is entering a particularly fruitful period of product development, with 10... Read more


Labour launches NHS election pledges

One hundred days before the UK election the Labour party has launched its pledge on the NHS, promising 36,000 mo... Read more


Genzyme extends Gaucher disease options in Europe

The European Commission (EC) has granted marketing authorisation for Genzyme's orphan drug Cerdelga (eliglustat)... Read more


Regeneron/Sanofi in pole position for PCSK inhibitor launch

Sanofi and Regeneron could have approval for their new cholesterol-lowering drug alirocumab in the US before the... Read more


Bayer’s Xarelto makes grade in NICE final draft guidance

In final draft guidance UK health watchdog NICE has confirmed its earlier positive draft decision recommending B... Read more


Novo Nordisk gets CHMP backing for obesity drug Saxenda

Novo Nordisk has won a Committee for Medicinal Products for Human Use (CHMP) endorsement for a higher-dose ve... Read more